Wyniki wyszukiwania - BazTech

1

Multi-parametric SPR – in vitro characterization method for biopharmaceuticals and drug delivery systems

Sadowski J. W., Granqvist N., Jokinen A.

Engineering of Biomaterials

|

2016

|

Vol. 19, no. 138 spec. iss.

120

2

Environmental and recombinant microorganisms for biopharmaceuticals production

Matejczyk M.

Budownictwo i Inżynieria Środowiska

|

2014

|

Vol. 5, no. 1

15--21

EN

Current, very fast development of genetic engineering and protein engineering (main segments of modern biotechnology) is a good way for commercially production of proteins, which benefit biopharmaceutical, the enzyme and agricultural industries. These products augment the fields of medicine, diagnostics, food, nutrition, detergents, textiles, leather, paper, pulp, polymers and plastics. Proteins with biopharmaceutical application are mainly clinical reagents, vaccines and drugs. During the last decade, the pharmaceutical biotechnology represents the fastest growing segment in the biotechnology sector. Production of recombinant proteins for use as pharmaceuticals, is a multi-billion dollar industry. One third of the biopharmaceuticals has come from microorganisms, such as Escherichia coli and yeast. The selection of expression systems depends on the size and biochemical status of proteins. Large proteins and proteins that require glycosylation are usually expressed in a mammalian cells, fungi or the baculovirus system. Smaller proteins are produced by prokaryotic cells. There are some very useful advantages for prokaryotic recombinant expression systems: it is easy of culture, very rapid cell growth with possibility of IPTG expression induction and quite simple product purification. On the other hand, for very large proteins, for S-S rich proteins and proteins which require post-translational modifications, bacteria, usually E. coli strains are not robust system. Better are yeasts with very popular species Saccharomyces cerevisiae and Pichia pastoris. This article presents the current application of microbes as production platforms for recombinant proteins and its genetic engineering for the use as biopharmaceuticals.

3

Specyfika kanałów dystrybucji leków biofarmaceutycznych zagranicznej firmy produkcyjnej na rynku polskim

Odlanicka-Poczobutt M.

Zeszyty Naukowe. Organizacja i Zarządzanie / Politechnika Śląska

|

2012

|

z. 60

247-258

PL

W artykule scharakteryzowano kanały dystrybucji leków biofarmaceutycznych wykorzystywanych przez grupę BMS (Bristol Myers Squibb) - producenta zagranicznego działającego na rynku polskim. Omówiono kanały poszczególnych firm działających w ramach grupy, ze wskazaniem specyfiki ich działalności. Przeprowadzone studium przypadku poprzedzono ogólną charakterystyką sytuacji na polskim rynku farmaceutycznym.

EN

In the article delivery channels of biopharmaceutical medicines used by the BMS group (Bristol Squibb Myers ) - foreign producer acting on the Polish market were characterized Channels of individual companies acting in frames of the group were with showing the specificity their activity. The conducted case study was preceded by an overall description of the situation on the Polish pharmaceutical market.